Activation of the Ca2+ activated Cl- channel TMEM16A is proposed as a treatment in inflammatory airway disease. It is assumed that activation of TMEM16A will induce electrolyte secretion, and thus reduce airway mucus plugging and improve mucociliary clearance. A benefit of activation of TMEM16A was shown in vitro and in studies in sheep, but others reported an increase in mucus production and airway contraction by activation of TMEM16A. We analyzed expression of TMEM16A in healthy and inflamed human and mouse airways and examined the consequences of activation or inhibition of TMEM16A in asthmatic mice. TMEM16A was found to be upregulated in the lungs of patients with asthma or cystic fibrosis, as well as in the airways of asthmatic mice. Activation or potentiation of TMEM16A by the compounds Eact or brevenal, respectively, induced acute mucus release from airway goblet cells and induced bronchoconstriction in mice in vivo. In contrast, niclosamide, an inhibitor of TMEM16A, blocked mucus production and mucus secretion in vivo and in vitro. Treatment of airway epithelial cells with niclosamide strongly inhibited expression of the essential transcription factor of Th2-dependent inflammation and goblet cell differentiation, SAM pointed domain-containing ETS-like factor (SPDEF). Activation of TMEM16A in people with inflammatory airway diseases is likely to induce mucus secretion along with airway constriction. In contrast, inhibitors of TMEM16A may suppress pulmonary Th2 inflammation, goblet cell metaplasia, mucus production, and bronchoconstriction, partially by inhibiting expression of SPDEF.

Department of Pathology University of Leuven UZ Leuven Campus Gasthuisberg Herestraat 49 B 3000 Leuven Belgium

Department of Pediatrics 2nd Faculty of Medicine University Hospital Motol Charles University Prague Celetná 13 116 36 Prague Czech Republic

Iaterion Oakland CA 94611 USA

Physiological Institute University of Regensburg Germany University Street 31 D 93053 Regensburg Germany

000      

00000naa a2200000 a 4500

001      

bmc21025310

003      

CZ-PrNML

005      

20211026133932.0

007      

ta

008      

211013s2021 sz f 000 0|eng||

009      

AR

024    7_

$a 10.3390/ijms22157852 $2 doi

035    __

$a (PubMed)34360618

040    __

$a ABA008 $b cze $d ABA008 $e AACR2

041    0_

$a eng

044    __

$a sz

100    1_

$a Centeio, Raquel $u Physiological Institute, University of Regensburg, Germany University Street 31, D-93053 Regensburg, Germany

245    10

$a Mucus Release and Airway Constriction by TMEM16A May Worsen Pathology in Inflammatory Lung Disease / $c R. Centeio, J. Ousingsawat, I. Cabrita, R. Schreiber, K. Talbi, R. Benedetto, T. Doušová, EK. Verbeken, K. De Boeck, I. Cohen, K. Kunzelmann

520    9_

$a Activation of the Ca2+ activated Cl- channel TMEM16A is proposed as a treatment in inflammatory airway disease. It is assumed that activation of TMEM16A will induce electrolyte secretion, and thus reduce airway mucus plugging and improve mucociliary clearance. A benefit of activation of TMEM16A was shown in vitro and in studies in sheep, but others reported an increase in mucus production and airway contraction by activation of TMEM16A. We analyzed expression of TMEM16A in healthy and inflamed human and mouse airways and examined the consequences of activation or inhibition of TMEM16A in asthmatic mice. TMEM16A was found to be upregulated in the lungs of patients with asthma or cystic fibrosis, as well as in the airways of asthmatic mice. Activation or potentiation of TMEM16A by the compounds Eact or brevenal, respectively, induced acute mucus release from airway goblet cells and induced bronchoconstriction in mice in vivo. In contrast, niclosamide, an inhibitor of TMEM16A, blocked mucus production and mucus secretion in vivo and in vitro. Treatment of airway epithelial cells with niclosamide strongly inhibited expression of the essential transcription factor of Th2-dependent inflammation and goblet cell differentiation, SAM pointed domain-containing ETS-like factor (SPDEF). Activation of TMEM16A in people with inflammatory airway diseases is likely to induce mucus secretion along with airway constriction. In contrast, inhibitors of TMEM16A may suppress pulmonary Th2 inflammation, goblet cell metaplasia, mucus production, and bronchoconstriction, partially by inhibiting expression of SPDEF.

650    _2

$a zvířata $7 D000818

650    _2

$a anoctamin 1 $x genetika $x metabolismus $7 D000075369

650    _2

$a bronchiální astma $x etiologie $x metabolismus $x patologie $7 D001249

650    _2

$a stenóza $x komplikace $7 D003251

650    _2

$a cystická fibróza $x etiologie $x metabolismus $x patologie $7 D003550

650    _2

$a HEK293 buňky $7 D057809

650    _2

$a lidé $7 D006801

650    _2

$a zánět $x etiologie $x metabolismus $x patologie $7 D007249

650    _2

$a myši $7 D051379

650    _2

$a hlen $x metabolismus $7 D009093

650    _2

$a respirační sliznice $x metabolismus $x patologie $7 D020545

655    _2

$a časopisecké články $7 D016428

700    1_

$a Ousingsawat, Jiraporn $u Physiological Institute, University of Regensburg, Germany University Street 31, D-93053 Regensburg, Germany

700    1_

$a Cabrita, Inês $u Physiological Institute, University of Regensburg, Germany University Street 31, D-93053 Regensburg, Germany

700    1_

$a Schreiber, Rainer $u Physiological Institute, University of Regensburg, Germany University Street 31, D-93053 Regensburg, Germany

700    1_

$a Talbi, Khaoula $u Physiological Institute, University of Regensburg, Germany University Street 31, D-93053 Regensburg, Germany

700    1_

$a Benedetto, Roberta $u Physiological Institute, University of Regensburg, Germany University Street 31, D-93053 Regensburg, Germany

700    1_

$a Doušová, Tereza $u Department of Pediatrics, Second Faculty of Medicine, University Hospital Motol, Charles University in Prague, Celetná 13, 116 36 Prague, Czech Republic

700    1_

$a Verbeken, Eric K $u Department of Pathology, University of Leuven, UZ Leuven Campus Gasthuisberg, Herestraat 49, B-3000 Leuven, Belgium

700    1_

$a De Boeck, Kris $u Department of Pathology, University of Leuven, UZ Leuven Campus Gasthuisberg, Herestraat 49, B-3000 Leuven, Belgium

700    1_

$a Cohen, Isaac $u Iaterion, Oakland, CA 94611, USA

700    1_

$a Kunzelmann, Karl $u Physiological Institute, University of Regensburg, Germany University Street 31, D-93053 Regensburg, Germany

773    0_

$w MED00176142 $t International journal of molecular sciences $x 1422-0067 $g Roč. 22, č. 15 (2021)

856    41

$u https://pubmed.ncbi.nlm.nih.gov/34360618 $y Pubmed

910    __

$a ABA008 $b sig $c sign $y p $z 0

990    __

$a 20211013 $b ABA008

991    __

$a 20211026133938 $b ABA008

999    __

$a ok $b bmc $g 1714387 $s 1145817

BAS    __

$a 3

BAS    __

$a PreBMC

BMC    __

$a 2021 $b 22 $c 15 $e 20210722 $i 1422-0067 $m International journal of molecular sciences $n Int J Mol Sci $x MED00176142

GRA    __

$a SRC013 $p Cystic Fibrosis Trust

GRA    __

$a DFG KU756/14-1 $p Deutsche Forschungsgemeinschaft

GRA    __

$a Mucus $p Gilead Sciences

LZP    __

$a Pubmed-20211013